Celgene’s Abraxane INJ extended its indication to lung cancer after pancreatic cancer
Celgene Korea (CEO Ah-kyung Kim), a global pharmaceutical company specializing in cancer, unveiled on the 31st that its ‘Abraxane INJ’ acquired an additional approval to add a non-small cell lung cancer indication from the Ministry of Food and Drug Safety.
Abraxane INJ, a primary therapy agent t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
